These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 14586159)

  • 21. Health-related quality of life in methylphenidate-treated children with attention-deficit-hyperactivity disorder: results from a Taiwanese sample.
    Yang P; Hsu HY; Chiou SS; Chao MC
    Aust N Z J Psychiatry; 2007 Dec; 41(12):998-1004. PubMed ID: 17999272
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined methylphenidate and atomoxetine pharmacotherapy in attention deficit hyperactivity disorder.
    Ozbaran B; Kose S; Yuzuguldu O; Atar B; Aydin C
    World J Biol Psychiatry; 2015; 16(8):619-24. PubMed ID: 26223958
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between dopamine transporter (DAT1) genotype, left-sided inattention, and an enhanced response to methylphenidate in attention-deficit hyperactivity disorder.
    Bellgrove MA; Hawi Z; Kirley A; Fitzgerald M; Gill M; Robertson IH
    Neuropsychopharmacology; 2005 Dec; 30(12):2290-7. PubMed ID: 16123773
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of methylphenidate on subtypes of attention-deficit/hyperactivity disorder.
    Gorman EB; Klorman R; Thatcher JE; Borgstedt AD
    J Am Acad Child Adolesc Psychiatry; 2006 Jul; 45(7):808-16. PubMed ID: 16832317
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of OROS methylphenidate on encopresis in children with attention-deficit/hyperactivity disorder.
    Yılmaz S; Bilgiç A; Hergüner S
    J Child Adolesc Psychopharmacol; 2014 Apr; 24(3):158-60. PubMed ID: 24168715
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Methylphenidate treatment and dyskinesia in children with attention-deficit/hyperactivity disorder.
    Balázs J; Dallos G; Keresztény A; Czobor P; Gádoros J
    J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):133-8. PubMed ID: 21486166
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Parental quality of life and depressive mood following methylphenidate treatment of children with attention-deficit hyperactivity disorder.
    Kim Y; Kim B; Chang JS; Kim BN; Cho SC; Hwang JW
    Psychiatry Clin Neurosci; 2014 Jul; 68(7):506-14. PubMed ID: 24417707
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
    Chou WJ; Chou MC; Tzang RF; Hsu YC; Gau SS; Chen SJ; Wu YY; Huang YF; Liang HY; Cheng H
    Psychiatry Clin Neurosci; 2009 Apr; 63(2):167-75. PubMed ID: 19335386
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder.
    Schulz KP; Fan J; Bédard AC; Clerkin SM; Ivanov I; Tang CY; Halperin JM; Newcorn JH
    Arch Gen Psychiatry; 2012 Sep; 69(9):952-61. PubMed ID: 22945622
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of methylphenidate in patients with cerebral palsy and attention-deficit hyperactivity disorder (ADHD).
    Gross-Tsur V; Shalev RS; Badihi N; Manor O
    J Child Neurol; 2002 Dec; 17(12):863-6. PubMed ID: 12593456
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential therapeutic effects of 12-week treatment of atomoxetine and methylphenidate on drug-naïve children with attention deficit/hyperactivity disorder: A counting Stroop functional MRI study.
    Chou TL; Chia S; Shang CY; Gau SS
    Eur Neuropsychopharmacol; 2015 Dec; 25(12):2300-10. PubMed ID: 26409297
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum levels of cortisol, dehydroepiandrosterone, and oxytocin in children with attention-deficit/hyperactivity disorder combined presentation with and without comorbid conduct disorder.
    Işık Ü; Bilgiç A; Toker A; Kılınç I
    Psychiatry Res; 2018 Mar; 261():212-219. PubMed ID: 29324397
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Time course and predictors of health-related quality of life improvement and medication satisfaction in children diagnosed with attention-deficit/hyperactivity disorder treated with the methylphenidate transdermal system.
    Frazier TW; Weiss M; Hodgkins P; Manos MJ; Landgraf JM; Gibbins C
    J Child Adolesc Psychopharmacol; 2010 Oct; 20(5):355-64. PubMed ID: 20973706
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dehydroepiandrosterone sulfate, free testosterone, and sex hormone-binding globulin on susceptibility to attention-deficit/hyperactivity disorder.
    Wang LJ; Lee SY; Chou MC; Lee MJ; Chou WJ
    Psychoneuroendocrinology; 2019 May; 103():212-218. PubMed ID: 30711898
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modulation of attention-deficit/hyperactivity disorder symptoms by short- and long-acting methylphenidate over the course of a day.
    Günther T; Kahraman-Lanzerath B; Knospe EL; Herpertz-Dahlmann B; Konrad K
    J Child Adolesc Psychopharmacol; 2012 Apr; 22(2):131-8. PubMed ID: 22364402
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Methylphenidate effects on blood serotonin and melatonin levels may help to synchronise biological rhythms in children with ADHD.
    Molina-Carballo A; Naranjo-Gómez A; Uberos J; Justicia-Martínez F; Ruiz-Ramos MJ; Cubero-Millán I; Contreras-Chova F; Augustin-Morales MD; Khaldy-Belkadi H; Muñoz-Hoyos A
    J Psychiatr Res; 2013 Mar; 47(3):377-83. PubMed ID: 23088865
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures.
    Posey DJ; Aman MG; McCracken JT; Scahill L; Tierney E; Arnold LE; Vitiello B; Chuang SZ; Davies M; Ramadan Y; Witwer AN; Swiezy NB; Cronin P; Shah B; Carroll DH; Young C; Wheeler C; McDougle CJ
    Biol Psychiatry; 2007 Feb; 61(4):538-44. PubMed ID: 17276750
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-acting methylphenidate reduces collision rates of young adult drivers with attention-deficit/hyperactivity disorder.
    Cox DJ; Davis M; Mikami AY; Singh H; Merkel RL; Burket R
    J Clin Psychopharmacol; 2012 Apr; 32(2):225-30. PubMed ID: 22367664
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Venlafaxine versus methylphenidate in pediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial.
    Zarinara AR; Mohammadi MR; Hazrati N; Tabrizi M; Rezazadeh SA; Rezaie F; Akhondzadeh S
    Hum Psychopharmacol; 2010 Nov; 25(7-8):530-5. PubMed ID: 20860068
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rate dependency revisited: understanding the effects of methylphenidate in children with attention deficit hyperactivity disorder.
    Teicher MH; Polcari A; Anderson CM; Andersen SL; Lowen SB; Navalta CP
    J Child Adolesc Psychopharmacol; 2003; 13(1):41-51. PubMed ID: 12804125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.